

UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences Presents:

2021 Virtual ASCO Review

Date: Friday, October 29, 2021

Time: Registration begins at 7:30 am
Conference: 8:00 am – 3:30 pm

Location: This conference will be held virtually via Microsoft Teams

Course Directors:

Antoinette Wozniak, MD, FACP, FASCO

Professor of Medicine

Associate Director, Clinical Research, UPMC Hillman Cancer Center
University of Pittsburgh School of Medicine

John Rhee, MD

Clinical Assistant Professor of Medicine
UPMC Hillman Cancer Center

Program Goal:

To provide a comprehensive overview of topics of greatest importance as presented at the 2021 ASCO Annual Meeting.

Target Audience:

Oncologists and other health care professionals working with individuals with cancer.

Course Objectives:

Upon completion of this conference the participant should be able to:

- Integrate new evidence into everyday clinical practice, thereby improving the quality of care being delivered to cancer patients.
- Implement practice changes in a variety of treatment options for solid tumors, including lung, breast, melanoma, colorectal, non-colorectal GI, and GU cancers.
- Stimulate innovative strategies for new and/or additional research related to treatment and/or prevention.
- Recognize the implications for practice change in both the academic and community practice settings.

Presentation Slides:

Instructions on how to access virtual conference and presentations will be sent to the email listed at registration. A copy of presentation slides can be accessed via OneDrive after the conference.

Accreditation and Designation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 5.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.75 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity

Agenda

7:30 am	Teams Log In	
8:00 am	Introduction & Welcome	Antoinette Wozniak, MD Taofeek Owonikoko, MD
8:10 am	Breast cancer	Adam Brufsky, MD Shannon Puhalla, MD
9:10 am	Head and Neck cancer	Dan P Zandberg MD
9:40 am	Break	
9:50 am	Lung Cancer	Liza Villaruz, MD Dan Petro, MD
10:50 am	Colorectal Cancer	Anu Krishnamurthy, ND
11:40 am	Non-Colorectal GI Cancer	John Rhee, MD
12:10 pm	Lunch	
12:50 pm	Melanoma	Yanna Najjar, MD
1:20 pm	Immunology	Jason Luke
2:20 pm	GU cancer	Len Appleman, MD Roby Thomas, MD
2:50 pm	Adjournment	

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Faculty

<p>Leonard J. Appleman MD PhD Director, Genitourinary Cancer Disease Section Associate Professor of Medicine University of Pittsburgh Department of Medicine, Division of Hematology/Oncology</p> <p>Adam Brufsky, MD, PhD, FACP Professor of Medicine University of Pittsburgh School of Medicine Associate Division Chief Division of Hematology/Oncology University of Pittsburgh School of Medicine Medical Director, Co-Director, Comprehensive Breast Cancer Center Magee-Women's Hospital of UPMC</p> <p>Anuradha Krishnamurthy, MD Faculty – Clinician, Physician UPMC Hillman Cancer Center</p> <p>Yana G. Najjar, MD Assistant Professor of Medicine Director, Clinical and Translational Research Center UPMC Hillman Cancer Center</p> <p>Taofeek Owonikoko, MD Faculty, research, Physician University of Pittsburgh Department of Medicine, Division of Hematology/Oncology</p>	<p>Dan Petro, MD Assistant Clinical Professor of Medicine Regional Medical Director UPMC Hillman Cancer Center</p> <p>Shannon Puhalla, MD UPMC Hillman Cancer Center UPMC Passavant UPMC Magee</p> <p>John C. Rhee, M.D. Clinical Assistant Professor of Medicine University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center</p> <p>Roby A. Thomas Hematologist Oncologist Department of Hematology/Oncology University of Pittsburgh Medical Center Hillman Cancer Center</p> <p>Liza C. Villaruz, MD Associate Professor of Medicine UPMC Hillman Cancer Center</p> <p>Antoinette J. Wozniak, MD Professor of Medicine Associate Director, Clinical Research, UPMC Hillman Cancer Center University of Pittsburgh School of Medicine, Director, Lung Cancer Disease Center</p> <p>Dan P Zandberg MD Associate Professor of Medicine Director, Head and Neck and Thyroid Cancer Disease Sections Division of Hematology/Oncology UPMC Hillman Cancer Center</p>
---	--

Faculty Disclosures:

All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:

- Antoinette J. Wozniak, MD – Consultant: Lilly Oncology, Regeneron, Epizyme, GlaxoSmith Kline, Novocure, Janssen Inc, Incyte, and Beigene. Other: DSMB BeyondSpring, DSMB Odrionate, DSMB HUVA.
- Jason Luke, MD – Other: DSNB AbbVie, DSMB Immutep, Other/Advisory Board: (7 Hills, Fstar, Inzen, Refle Xion, Xilio, Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, Onc.AI, Pyxis, Tempest, Consultant: AbbVie, Alnylam, Avillion, Bayer, Bristol Meyer Squibb, Checkmate, Codiak, Crown, Day One, Eisai, EMD Serono, Flame, Genentech, Gilead, HotSpot, Kadmon, KSQ, Janssen, Ikena, Immunocore, Incyte, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, Synthekine, TRex, Werewolf, Xencor Research and Support: AbbVie, Agios (IIT), Astellas, AstraZeneca, Bristol-Meyers Squibb (IIT and Industry), Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Pfizer (IIT and Industry), Replimmune, Rubis, Scholar rock, Synlogic, Takeda, Trishula, Tizona, Xencor Patents: (both provisional) Serial # 15/612,657, (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1: Diagnostic, Prognostic and Therapeutic Uses Thereof)
- Dan Zandberg, MD – Grant/Research Support: (for my role as PI for trails with): Merck, Bristol Myers-Squibb, Aduro, Glaxo Smith-Kline, Lilly, Checkmate Pharmaceuticals, BICARA, Aethlon, Prelude Therapeutics Consultant: Macrogenics, Blueprint Medicine
- Shannon Puhalla, MD – Grant/Research Support: AbbVie, Pfizer, Lilly, Novartis, Incyte, Covariance-Bayer, AstraZeneca.
Consultant: AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Eisai, nanostring.
- Adam Brufsky, MD, PhD, FACP – Consultant: Roche, Puma, Seattle Genetics, AstraZeneca, Daiichi, Pfizer, Novartis.
- Yana Najjar, MD – Grant/Research Support: Merck, Bristol Meyer Squibb, Pfizer Consultant: Novartis, Array BioPharma, Merck
- Leonard Appleman, MD, PhD – Consultant: AADi Grant/Research Support: Pfizer, Exelixis, Bristol Meyer Squibb, Astellas Pharma, Novartis, Bayer, Merck, Genentech/Roche, AVEO, Peleton Therapeutics, Calithera Bioscience, Seattle Genetics, Inovia Pharmaceuticals, Eisai, Lilly, Amgen, Surface Oncology, BioNTech, Epizyme.
Other: Pfizer, Exelixis
- Taofeek Owonikoko, MD – Research/Funding: Novartis, Astellas Pharma, Bayer, StemCentRX, Regeneron, AstraZeneca, G1 Therapeutics, Bristol Myers, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer Aeglea Biotherapeutics, Incyte, Merck, Mersana, Turning Point, Oncorus, Ipsen, Eisai, Roche/Genentech Consultant/Advisory Board: Novartis, Lilly, Sandoz, AbbVie, Eisai, G1 Therapeutics, Bristol-Meyer Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, XCover, Bayer, heron Pharmaceutical, ARMO, BioScience, Merck, Bayer, Jazz, Zentalis, Ipsen IRC/DSMB: Serono, Roche/Genentech, Other: Cambium Oncology

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

We gratefully acknowledge support from the following for this activity:

Exhibitors:

AstraZeneca

Eisai Oncology

Advanced Accelerator Applications

Lilly Oncology

Seagen

Agendia, Inc

Merck & Co. Inc

Bristol Meyers Squibb

Genentech "A member of the Roche Group"

Novartis Oncology